STOCKSCOPE

Critica (ASX: CRI) Unveils $2 Billion Rare Earth Project Valuation, but Can It Fund Jupiter's Development?

Mark Elzayed

Mark Elzayed

CIO at Vestra Capital

Published:28 Oct 2026
Critica (ASX: CRI) Unveils $2 Billion Rare Earth Project Valuation, but Can It Fund Jupiter's Development?

Critica Limited (ASX: CRI) has outlined a potentially transformative development opportunity at its Jupiter Rare Earth Elements Project in Western Australia, with a new Scoping Study estimating an after-tax net present value of almost $2 billion.

Released on 20 October 2026, the study presents compelling preliminary economics for a large-scale rare earth operation. However, its estimated $556 million construction requirement raises an important question: can Critica convert Jupiter's substantial resource base into a financially viable mining business?

Key numbers

  • $1.99 billion: Modelled after-tax net present value at an 8% discount rate.
  • 48.4%: Estimated after-tax internal rate of return.
  • $555.5 million: Estimated pre-production capital expenditure.
  • 1.7 billion tonnes: Jupiter Mineral Resource grading 1,700 parts per million total rare earth oxides.
  • 8,300 tonnes annually: Average contained rare earth oxides in mixed rare earth carbonate over the proposed operating life.

A $2 billion development case changes Jupiter's outlook

Critica's October Scoping Study represents its most significant step towards establishing Jupiter as a commercial rare earth development.

The proposed operation would process approximately 8 million tonnes of ore annually through conventional open-pit mining, beneficiation and hydrometallurgical processing.

The study forecasts approximately $12.3 billion in life-of-mine revenue over a 14-year processing period.

Average annual EBITDA is estimated at $446 million, while the modelled after-tax payback period is approximately two years after operations commence.

These figures suggest substantial potential cash generation if the project reaches production under the study's assumptions.

However, the financial projections remain preliminary and depend heavily on commodity prices, metallurgical performance, capital costs and successful project financing.

The study does not establish Ore Reserves or guarantee commercial viability.

Resource confidence strengthens the proposed mine plan

One of Jupiter's most important developments occurred on 12 October, when Critica announced its first Indicated Mineral Resource.

The upgraded estimate includes approximately 160 million tonnes of Indicated Resources within the broader 1.7-billion-tonne inventory.

Crucially, approximately 97% of the Scoping Study's 107-million-tonne production target comes from Indicated Resources.

This provides a stronger geological foundation for preliminary mine planning than a development case relying predominantly on lower-confidence Inferred Resources.

The proposed production target represents only around 6% of Jupiter's total Mineral Resource, leaving considerable scope for future resource conversion and potential mine-life extensions.

Nevertheless, expanding the mine plan would require additional studies and economic justification.

Processing improvements could support stronger margins

Critica has also made meaningful progress in developing Jupiter's rare earth processing technology.

Pilot-scale beneficiation testing demonstrated approximately 71% total rare earth oxide recovery, while subsequent optimisation achieved a fourteenfold concentration upgrade and rejected approximately 95% of the original feed mass.

Reducing the volume requiring downstream chemical processing could lower reagent consumption, equipment requirements and operating costs.

The company's proposed mixed rare earth carbonate contains commercially important magnet rare earth elements, including neodymium, praseodymium, dysprosium and terbium.

These materials are used in permanent magnets for electric vehicles, wind turbines and advanced industrial applications.

However, Critica has not secured binding offtake or pricing agreements.

Actual product payability and processing costs remain critical uncertainties.

The $556 million funding challenge cannot be ignored

Despite encouraging project economics, Critica remains a development-stage company without established commercial rare earth production.

Its estimated pre-production expenditure of $555.5 million carries Scoping Study-level accuracy of approximately plus or minus 35%.

The estimate excludes additional working capital and financing requirements.

The company has not secured the necessary development funding.

Future financing could involve equity, debt, strategic partnerships or offtake-linked arrangements, potentially creating dilution or additional financial obligations.

Conventional earnings multiples therefore provide limited valuation insight.

A risk-adjusted assessment of Jupiter's projected cash flows, capital requirements and probability of development is more appropriate than treating the study's $1.99 billion valuation as an established asset value.

Insight: Jupiter's strongest advantage may be its limited initial mining footprint

What stands out to us is that Critica's proposed development uses only 6% of Jupiter's total Mineral Resource while generating a modelled after-tax valuation approaching $2 billion. This provides potential expansion opportunities without requiring the entire resource to become commercially viable. However, the opportunity depends on proving reliable metallurgical recoveries, competitive operating costs and access to substantial development capital. We believe the most important next test will be whether advanced technical studies preserve Jupiter's projected economics while reducing uncertainty around the $555.5 million funding requirement.

The verdict: Strong preliminary economics still require execution

Critica has established a more credible development pathway through resource upgrades, processing improvements and encouraging preliminary financial projections.

The opportunity is substantial, but commercial success remains conditional on financing, technical validation and binding customer arrangements.

The next phase of engineering studies and funding discussions will determine whether Jupiter can progress from a promising rare earth resource towards a commercially sustainable operation.

Mark Elzayed

Mark Elzayed

(CIO at Vestra Capital)

Mark Elzayed is a prominent Australian financial executive and portfolio strategist with over a decade of hands-on capital markets experience. Having successfully managed over $100M+ in FUM across volatile economic cycles, Mark founded Vestra Capital to democratize institutional-grade quantitative strategies and privileged ASX deal flow for Australian investors.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...